JPRN-UMIN000006341尚未招募未知
A randomized, open-label trial of ramelteon to prevent postoperative delirium in patients undergoing coronary artery bypass grafting - Trial of ramelteon to prevent postoperative delirium in patients undergoing coronary artery bypass grafting
Shimane University faculty of medicine0 个研究点目标入组 50 人开始时间: 2011年9月13日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •hepatic impairment taking fluvoxamine maleate
研究者
相似试验
招募中
3 期
Randomized controlled trials of ramelteon treatment for nocturia with sleep disorders after treatment for prostate cancer brachytherapy.Prostate cancerJPRN-UMIN000006711Yokohama city university school of medicine department of urology100
进行中（未招募）
不适用
A randomised, controlled, open-label trial to compare brachial artery reactivity and cardiovascular risk of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple combination therapy containing DRV/r in HIV-1 infected subjects with undetectable plasma HIV-1 RNA on their current treatments. - NDEUCTR2008-002383-34-ITJANSSEN-CILAG
进行中（未招募）
不适用
A randomised, controlled, open-label trial to compare the efficacy, safety and tolerability of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple combination therapy containing DRV/r in HIV-1 infected subjects with undetectable plasma HIV-1 RNA on their current treatments.HIV-1MedDRA version: 9.1Level: LLTClassification code 10020161Term: HIV infectionEUCTR2006-006437-40-ATJanssen-Cilag International NV250
尚未招募
不适用
Analyzing the requirements of platelets transfusion in stem cell transplant and high dose chemotherapy patients by giving with or without romiplostim.CTRI/2021/12/038468Dr Sachin Suresh Jadhav
进行中（未招募）
1 期
A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects. - This trial will be referred to as ARTEMIS.EUCTR2005-002486-36-GBTibotec Pharmaceuticals Limited